The development of novel delivery systems is an important initiative in the biotechnology industry.
Traditionally, the introduction of biologics, small molecules, and peptides into a mammal’s body has been limited to delivery methods such as intramuscular, intravenous, rectal, and oral. These first routes are considered invasive, while the latter tends to be imprecise, slow-acting (often requiring a loading phase of weeks to months), and less effective, in comparison (in some cases being completely metabolized, ultimately rendering them ineffective).
As demand increases for efficient, results-oriented treatments and new, non-invasive alternatives to costly procedures, more effective delivery options have become a necessity.
Transdermal delivery is recognized as one of the most promising and advantageous opportunities, but the primary challenge has been penetrating the barriers of the epidermis, in particular the stratum corneum.
An ideal solution would be to employ a delivery method that leverages a topical application directly to the skin, but this type of targeted intervention is typically impossible in the body due to the protective barrier of the skin.
For a transdermal delivery method to be effective, the desired ingredient, as part of a formulation that is topically applied to the skin, must be able to penetrate the outermost barrier of the epidermis, the stratum corneum, before being delivered to its site of action in the necessary concentrations. Apart from specific transport mechanisms, in general, hydrophilic molecules are not able to penetrate the stratum corneum effectively due to its lipophilic properties; therefore, obtaining skin bioavailability of hydrophilic substances, like peptides, has posed a challenge.
OPI’s patent pending delivery system allows our scientists to bypass the lipophilic barrier of the skin, safely and non-invasively delivering biologics, small molecules, and peptides through the skin for prompt and direct use, precisely where they are needed.